Navigation Links
Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts

ORLANDO, Fla., July 30 /PRNewswire/ -- The Angelman Syndrome Foundation today announced the formation of the Angelman Treatment and Research Institute (ATRI), which will direct the organization's rapidly increasing research funding. The ATRI will also serve as a hub for more than 30 organizations, researchers and scientists worldwide to share discoveries and treatments for this neuro-genetic disorder. The announcement of the ATRI was made during the Angelman Syndrome Foundation's biennial conference in Orlando, Fla.

ATRI will realize the Angelman Syndrome Foundation's "scientific roadmap" that directs its aggressive funding of Angelman Syndrome (AS) research. AS occurs in one in every 15,000 live births and exhibits symptoms such as: developmental delay; lack of speech; seizures; inappropriate laughter; and walking and balance disorders. Short term focus of the roadmap is to fund research that finds treatments that may cure symptoms of AS while continuing ongoing research and clinical trials involving UBE3A, the gene with abnormalities in AS patients. Since AS shares symptoms with several other disorders, including autism, cerebral palsy, epilepsy, Rett Syndrome, and Prader-Willi Syndrome, any progress toward treating and curing symptoms has the potential to positively affect more than 12 million people.

"The creation of the Angelman Treatment and Research Institute is exciting and timely. The priorities as established by the ATRI are right on in recognizing the continued need for expanding our fundamental knowledge of UBE3A and its role in brain development and function," said Michael D. Ehlers, M.D., Ph.D., Department of Neurobiology at Duke University Medical Center. "The Angelman Syndrome Foundation is to be applauded in having the vision to recognize the critical importance of basic research and in setting this research on a trajectory toward a cure. I see a future of great opportunity and advance in neurodevelopmental disorders with Angelman Syndrome and the ATRI leading the way."

Research funding will also focus on new therapies for symptoms, pharmaceuticals, biological agents, adaptive devices, surgical and diagnostic procedures. An emphasis on adult AS patients will extend the scope of clinical trials to include a wide age group and investigate and advance life and self-help skills, vocational training, and access to community programs and health services.

"The Angelman Syndrome Foundation is committing $125,000 in seed funding to start ATRI with an ultimate goal of raising $2 million within two years," said Eileen Braun, Angelman Syndrome Foundation Executive Director. "Funding will be used to implement program goals while the Angelman Syndrome Foundation's Scientific Advisory Committee will continue administering grant reviews and making funding recommendations for innovative research."

ATRI will allow scientific members to conduct Web-based meetings and symposiums, and convene as necessary to discuss research progress and activities.

About Angelman Syndrome

Identified by Dr. Harry Angelman, AS occurs in one in every 15,000 live births and exhibits symptoms such as: developmental delay; lack of speech; seizures; inappropriate laughter; and walking and balance disorders. It is a life-long neuro-genetic disorder usually identified in patients between two and five years old. AS is often misdiagnosed as Autism and a cure has not yet been developed.

About Angelman Syndrome Foundation

The Angelman Syndrome Foundation, the leading resource for AS information, support and AS research funding was founded more than 20 years ago with the mission of advancing the awareness and treatment of AS through education and information, research and support for individuals with AS, their families and other concerned parties. Since 1996 the Angelman Syndrome Foundation has funded 51 research grants totaling over $2.5 million. The Angelman Syndrome Foundation has awarded a majority of these funds ($2.2 million) beginning in 2005. In November 2008, the Angelman Syndrome Foundation received Charity Navigator's 4-star rating for sound fiscal management. Only a quarter of all charities evaluated by Charity Navigator receive this distinction of demonstrating the ability to efficiently manage and grow its finances. For more information, please visit

SOURCE Angelman Syndrome Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Diabetes appears to increase risk of death for patients with acute coronary syndromes
2. Eye-staining technique offers early detection for dry eye syndrome
3. Pollen, Fruits, Veggies Help Trigger Oral Allergy Syndrome
4. Treating depression may improve recovery of heart rate variability following coronary syndromes
5. Stem cell research produces a key discovery for Fragile X Syndrome
6. Metabolic syndrome heightens risk for development of uric-acid kidney stones
7. Stomach Virus a Culprit in Chronic Fatigue Syndrome
8. Chronic fatigue syndrome linked to stomach virus
9. Toward a faster prenatal test for Down syndrome
10. Brain Defect Helps Drive Fragile X Syndrome
11. Drug Combo Helps Fight Marfan Syndrome
Post Your Comments:
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
(Date:11/26/2015)... San Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... accomplishment! On November 19, 2015, our surgeons performed their 6,000th free flap breast ... Ledoux , “We wake up every day excited to rebuild lives and it’s an ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film ... trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 ... with any font, giving users limitless opportunities to stylize and create designs quickly ...
(Date:11/26/2015)... ... ... Inc., developer and distributor of the world-class Asterisk based contact center software Q-Suite, announces ... new Q-Suite 6 platform is based on the latest Java Enterprise standards. By conforming ... of software for many key components of the suite. Much of the suite runs ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part ... For Empowerment ™ attracts volunteers together who want to combine talents and resources ... key stakeholders in the process. The non-profit launched its first major fundraiser on ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Monitoring (TDM) Market: Supplier Shares, Country ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "Radioimmunoassay Market by ... (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), ... Global Forecast to 2020" report to ... has announced the addition of the ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
Breaking Medicine Technology: